Company news
Cogent Biosciences, Inc. (NASDAQ:COGT) news
Cogent Biosciences, Inc. news releases on 6ix. Latest, Jan 8, 2025: Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare…
Press releases — page 2
Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
January 7, 2025
Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
December 8, 2024
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
December 7, 2024
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial Results
November 11, 2024
Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting
November 4, 2024
Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics
October 22, 2024
Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis
September 2, 2024
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results
August 5, 2024
Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT trial
June 26, 2024
Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
June 13, 2024
Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
May 22, 2024
Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting
May 22, 2024
Cogent Biosciences Reports First Quarter 2024 Financial Results
May 6, 2024
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
April 8, 2024
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
February 25, 2024
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
February 21, 2024
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement
February 13, 2024
Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting
February 4, 2024
Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
January 8, 2024
Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
January 1, 2024
Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
December 10, 2023
Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)
December 8, 2023
Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer Symposium
December 6, 2023
Cogent Biosciences to Host Investor Webcast on December 11, 2023 at 8:00 AM ET to Review Clinical Data Being Presented at American Society of Hematology (ASH) Annual Meeting
December 3, 2023
Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium
November 28, 2023
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results
November 1, 2023
Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 13, 2023
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results
August 7, 2023
Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock
June 8, 2023
Cogent Biosciences Announces Participation in the Jefferies Healthcare Conference
June 6, 2023
Cogent Biosciences Announces Proposed Public Offering of Common Stock
June 5, 2023
Cogent Biosciences Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST)
June 2, 2023
Cogent Biosciences to Host Investor Webcast to Discuss Lead-In Data Being Presented at ASCO from the Ongoing Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST)
May 22, 2023
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2023 Financial Results
May 8, 2023
Cogent Biosciences Presents Preclinical Data at AACR Annual Meeting Highlighting Precision Therapy Pipeline and Announces Initiation of Part 2 of the Registration-Enabling APEX Trial with Bezuclastinib in Advanced Systemic Mastocytosis
April 16, 2023
Cogent Biosciences Announces Participation at Upcoming Investor Conferences
April 11, 2023
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
March 13, 2023
Cogent Biosciences Announces Planned 2023 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Cancer Therapeutics
January 8, 2023
Cogent Biosciences Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
January 4, 2023
Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
December 10, 2022
Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis
December 4, 2022
Cogent Biosciences Appoints Rachael Easton, MD, Ph.D., VP, Head of Clinical Development
November 27, 2022
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results
November 13, 2022
Cogent Biosciences Announces Bezuclastinib Presentations at the 64th Annual American Society of Hematology (ASH) Meeting
November 2, 2022
Cogent Biosciences to Showcase Precision Therapy Pipeline at the EORTC-NCI-AACR Annual Meeting
October 25, 2022
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2022 Financial Results
August 8, 2022
Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 15, 2022
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock and Pre-funded Warrants
June 12, 2022
Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
June 9, 2022
Cogent Biosciences to Host Investor Webcast on June 10, 2022 at 8:00am ET
June 5, 2022